Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This study identified increased expression of ACAA1 and its regulation by hsa-miR-1343-3p, linking androgenetic alopecia to lipid metabolism pathways, particularly through PPAR signaling, in scalp tissues.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This study found that in male androgenic alopecia, the androgen receptor coactivator ARA70/ELE1 exhibits differential expression patterns, suggesting its involvement in the condition.

This study explored a dual-functional dressing with quaternized chitosan and magnesium, finding it enhanced wound healing and had strong antibacterial effects against drug-resistant bacteria in diabetic rat models with infected foot ulcers, suggesting promise for diabetic foot ulcer treatment.

This study identified a shared gene signature in scarring alopecia subtypes, with increased mast cell presence, suggesting similar treatment approaches may be effective across these hair loss disorders.

The man's hair loss and skin papules were diagnosed as atrichia with papular lesions, not alopecia areata universalis.

This review discusses the diverse applications of algae in non-energy sectors, including pharmaceuticals, food ingredients, pigments, and cosmetics, and reports no new experimental results.

This study reports the crystallization of the human androgen receptor's ligand-binding domain with nonsteroidal ligands, which may aid in understanding the differences in binding compared to steroidal ligands.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

This study identified rare nucleotide substitutions in the SLC39A4 gene in children with acrodermatitis enteropathica, suggesting a genetic component to the disease's etiology.

This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.

In this retrospective study from five Colombian cities, researchers detailed the clinical characteristics of 562 alopecia areata patients, noting that multiple plaques and the patchy subtype were common, with steroid injections frequently used as treatment.

This study found a positive association between bilateral diagonal earlobe crease and bilateral preauricular crease with coronary artery disease, with both creases together predicting the disease with 90% accuracy.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This study found that circAGK was highly expressed in AGA patients and promoted dermal papilla cell apoptosis, suggesting it as a potential target for treating androgen alopecia.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

In this study, intralesional triamcinolone acetonide was found to be more effective than platelet rich plasma and placebo for moderate to severe alopecia areata, but had a higher relapse rate.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

This study found that increased mRNA expression of the Ectodysplasin-A2-Receptor, observed across multiple species and tissues, may exacerbate inflammation during aging, suggesting potential benefits of blocking EDA2R/EDA-A2 signaling.

This paper highlights advances in Developmental Dynamics, noting how epoa-deficient zebrafish can model Diamond-Blackfan anemia like disorders for drug screening, Alx4 mouse models offer insights into craniofacial development, and mTORC1 signaling is crucial for retinal development.

This review discusses the roles of the Agouti and Agouti-related proteins in pigmentation and energy regulation and reports no new experimental findings.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Thorough clinical examination is crucial for diagnosing unusual alopecia.

This study found that cortexolone 17α-propionate (clascoterone) effectively inhibited androgen receptor-regulated transcription and IL-6 synthesis in scalp cells, potentially making it a promising candidate for topical treatment of androgenetic alopecia.

In this study, researchers used an integrated in silico approach to demonstrate that Polygonum multiflorum combats androgenetic alopecia via anthraquinone emodin, which targets PI3K catalytic subunits differently from traditional antiandrogenic treatments, showing potential as a novel therapeutic strategy.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.